vorolanib (EYP-1901) / EyePoint Pharma, Betta Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vorolanib (EYP-1901) / EyePoint Pharma
DAVIO2, NCT05381948: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

Active, not recruiting
2
160
US
Eyp-1901, Aflibercept 2Mg/0.05Ml Inj,Oph, Eylea
EyePoint Pharmaceuticals, Inc.
Wet Age-related Macular Degeneration
11/23
04/24
NCT05383209: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Recruiting
2
105
US
EYP-1901, Sham IVT
EyePoint Pharmaceuticals, Inc.
Nonproliferative Diabetic Retinopathy
02/24
08/25
VERONA, NCT06099184: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Not yet recruiting
2
25
NA
EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph
EyePoint Pharmaceuticals, Inc.
Diabetic Macular Edema
01/25
01/25

Download Options